Home › Funds › PSP Research LLC › VKTX

PSP Research LLC position in VKTX

VIKING THERAPEUTICS INC · Health Care

PSP Research LLC reported holding 10,000 shares of VKTX (VIKING THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$390K, representing 0.21% of its reported portfolio and ranking #37 among its reported holdings. PSP Research LLC has disclosed VKTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)10.00K sh
Reported value held$390.10K
Portfolio Weight0.21%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's VKTX position evolved

PSP Research LLC first disclosed a stake in VKTX in Q4 2025 at 14,714 shares (US$518K). Across 3 filings, PSP Research LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 10,000 shares valued at US$390K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 14.71K $517.64K New
Q1 2026 15.00K $488.10K Add
Q2 2026 10.00K $390.10K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VKTX and 13F data

VKTX (VIKING THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in VKTX — the largest reported positions include Vestal Point Capital, LP (US$26.5M), Eversept Partners, LP (US$23.5M), ADAR1 Capital Management, LLC (US$22.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VKTX

All VKTX fund holders →